Steven Nissen, MD, Discusses Historic Bempedoic Acid Labeling for CV Risk Reduction

FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia

Commentary

Video

CLEAR Outcomes PI Steven Nissen, MD, links findings from the pivotal trial with labeling updates that make bempedoic acid the only nonstatin agent approved to reduce CV risk.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

Steven Nissen, MD, spoke with Patient Care about the findings from the landmark CLEAR Outcomes trial that support the new labeling for bempedoic acid as the only non-statin drug indicated to reduce cardiovascular risk. Nissen is Chief Academic Officer, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH and the primary investigator for the bempedoic acid and bempedoic acid plus ezetimibe clinical trial program.

This is an excerpt from a longer interview; additional content will be available shortly.

Related Content

August 1st 2025

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

FDA Approves Finerenone for Heart Failure With LVEF ≥40% Following Positive Phase 3 Data

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

July 14th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.

August 30th 2023

Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

BF% outperforms BMI in Predicting Morality risk in young adults: New Findings / image courtesy of University of Florida

Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.

June 23rd 2025

FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia

Weight cycling significantly raises heart failure and metabolic disease risks, independent of baseline overweight, underscoring the importance of stable weight strategies.

Related Content

Cardiology

ACC

August 1st 2025

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

FDA Approves Finerenone for Heart Failure With LVEF ≥40% Following Positive Phase 3 Data

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

July 14th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.

August 30th 2023

Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.

June 23rd 2025